![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GLAXO.png)
Share the post "GlaxoSmithKline Pharmaceuticals ‘s Q3 2024-25 Latest News: Profit Rises by 402.48% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 17.56 % in the past year, decrease in net sales/revenue by -5.37 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 125.98 %. Marginal decrease of -4.93% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for GlaxoSmithKline Pharmaceuticals Limited. Notable increase of 402.48 % in net profit Year to Year, GlaxoSmithKline Pharmaceuticals Limited’s profitability dropped by -8.09 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS increased by 36.54 % Year to Year. EPS decreased by -6.64 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 804.98 Cr | Rs. 1000.05 Cr | Rs. 946.36 Cr | -5.37 % | + 17.56 % |
| Expenses | Rs. 587.47 Cr | Rs. 681.1 Cr | Rs. 656.18 Cr | -3.66 % | + 11.7 % |
| Operating Profit | Rs. 217.51 Cr | Rs. 318.95 Cr | Rs. 290.18 Cr | -9.02 % | + 33.41 % |
| OPM % | 27.02 % | 31.89 % | 30.66 % | -1.23 % | + 3.64 % |
| Other Income | Rs. -134.97 Cr | Rs. 36.88 Cr | Rs. 35.06 Cr | -4.93 % | + 125.98 % |
| Interest | Rs. 0.32 Cr | Rs. 0.27 Cr | Rs. 0.09 Cr | -66.67 % | -71.88 % |
| Depreciation | Rs. 17.11 Cr | Rs. 16.86 Cr | Rs. 18.8 Cr | + 11.51 % | + 9.88 % |
| Profit before tax | Rs. 65.11 Cr | Rs. 338.7 Cr | Rs. 306.35 Cr | -9.55 % | + 370.51 % |
| Tax % | 30.13 % | 26.58 % | 25.39 % | -1.19 % | -4.74 % |
| Net Profit | Rs. 45.49 Cr | Rs. 248.69 Cr | Rs. 228.58 Cr | -8.09 % | + 402.48 % |
| EPS in Rs | Rs. 2.69 | Rs. 14.68 | Rs. 13.49 | -8.11 % | + 401.49 % |
Today, we’re looking at GlaxoSmithKline Pharmaceuticals Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 17.56 %. However, it did see a marginal slip of -5.37 % from the previous quarter. Expenses decreased slightly by -3.66 % quarter-on-quarter, aligning with the annual rise of 11.7 %. Operating profit, while up 33.41 % compared to last year, faced a quarter-on-quarter dip of -9.02 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 3.64 %, but a shrinkage of -1.23 % sequentially. Other income fell by -4.93 % compared to the last quarter, despite an annual growth of 125.98 %. Interest expenses dropped significantly by -66.67 % from the previous quarter, yet the year-over-year decrease remains at a moderate -71.88 %. Depreciation costs climbed by 11.51 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 9.88 %. Profit before tax grew annually by 370.51 % but saw a reduction from the preceding quarter by -9.55 %.
Tax expenses as a percentage of profits decreased slightly by -4.74 % compared to last year, with a more notable quarter-on-quarter decrease of -1.19 %. Net profit rose by 402.48 % year-on-year but witnessed a -8.09 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 401.49 % but a quarterly fall of -8.11 %. In summary, GlaxoSmithKline Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 804.98 Cr | Rs. 1000.05 Cr | Rs. 946.36 Cr | -5.37 % | + 17.56 % |
| Expenses | Rs. 587.47 Cr | Rs. 681.1 Cr | Rs. 656.18 Cr | -3.66 % | + 11.7 % |
| Operating Profit | Rs. 217.51 Cr | Rs. 318.95 Cr | Rs. 290.18 Cr | -9.02 % | + 33.41 % |
| Net Profit | Rs. 45.49 Cr | Rs. 248.69 Cr | Rs. 228.58 Cr | -8.09 % | + 402.48 % |
| EPS in Rs | Rs. 2.69 | Rs. 14.68 | Rs. 13.49 | -8.11 % | + 401.49 % |
In reviewing GlaxoSmithKline Pharmaceuticals Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 17.56 % year-on-year growth, although there was a slight dip of -5.37 % from the previous quarter. Expenses rose by 11.7 % compared to the previous year, with a decrease of -3.66 % quarter-on-quarter. Operating Profit surged by 33.41 % annually, and saw a -9.02 % decrease from the last quarter.
Net Profit showed yearly increase of 402.48 %, and experienced a -8.09 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 401.49 % annually, however dipped by -8.11 % compared to the last quarter. In essence, while GlaxoSmithKline Pharmaceuticals Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
